Unraveling the mechanism of action of thiazolidinediones.

Thiazolidinediones (TZDs) are a new class of antidiabetic agents and include three compounds that have come to clinical use — troglitazone (Rezulin®), rosiglitazone (Avandia®), and pioglitazone (Actos®) — as well as several others that have been limited to pre-clinical study. TZDs were initially discovered by screening compounds for a hypoglycemic action in the ob/ob mouse (1), and subsequently they were shown to improve insulin action in a variety of obese and diabetic animal models with insulin resistance (2). In these model systems, TZDs reduce plasma glucose and insulin levels and improve some of the abnormalities of lipid metabolism. Consistent with animal studies, clinical studies have shown that treatment of type 2 diabetic patients with TZDs can lower serum glucose and insulin levels, increase peripheral glucose uptake, and decrease triglyceride levels (3). In euglycemic clamp studies, this is associated with an increase in insulin sensitivity in peripheral tissues (mainly represented by muscle in clamp studies), with relatively little effect on hepatic glucose output (4).

[1]  J. Olefsky.  Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[2]  K. Heidenreich,et al.  In vitro studies on the action of CS-045, a new antidiabetic agent. , 1990, Metabolism: clinical and experimental.

[3]  C. Kahn,et al.  Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes , 1999, Cell.

[4]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[5]  G. Shulman,et al.  Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. , 2000, The Journal of clinical investigation.

[6]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[7]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[8]  M. Olive,et al.  Life without white fat: a transgenic mouse. , 1998, Genes & development.

[9]  P. Puigserver,et al.  Transcriptional regulation of adipogenesis. , 2000, Genes & development.

[10]  P. Jansson,et al.  Insulin Signaling and Action in Fat Cells: Associations with Insulin Resistance and Type 2 Diabetes , 1999, Annals of the New York Academy of Sciences.

[11]  C. Kahn,et al.  Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. , 2000, Molecular cell.

[12]  S. Clarke,et al.  Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. , 1992, Molecular pharmacology.

[13]  G. Ailhaud,et al.  Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. , 1994, Molecular pharmacology.

[14]  K. Moulder,et al.  Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.

[15]  L. Chao,et al.  Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. , 2000, The Journal of clinical investigation.

[16]  C. Burant,et al.  Troglitazone action is independent of adipose tissue. , 1997, The Journal of clinical investigation.

[17]  R. Bergman,et al.  Free Fatty Acids and Pathogenesis of Type 2 Diabetes Mellitus , 2000, Trends in Endocrinology & Metabolism.

[18]  C. Kahn,et al.  A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. , 1998, Molecular cell.

[19]  K. Umesono,et al.  Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. , 1998, The Journal of clinical investigation.

[20]  G. Shulman,et al.  Mechanism of Insulin Resistance in A-ZIP/F-1 Fatless Mice* , 2000, The Journal of Biological Chemistry.

[21]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[22]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[23]  T. Fujiwara,et al.  Characterization of New Oral Antidiabetic Agent CS-045: Studies in KK and ob/ob Mice and Zucker Fatty Rats , 1988, Diabetes.

[24]  T. Kadowaki,et al.  Insights into insulin resistance and type 2 diabetes from knockout mouse models. , 2000, The Journal of clinical investigation.

[25]  B. Spiegelman,et al.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.

[26]  J. Hoofnagle,et al.  Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes , 2000, Annals of Internal Medicine.